Mumbai, April 30 -- The broker cited a favourable outlook supported by the company's ability to scale up high-margin products and secure more long-term contracts, which could potentially enhance both growth and valuations.

The brokerage noted that Blue Jet's advanced research and development capabilities, along with its backward integration and expertise in complex chemistries, position it well to serve both regulated and emerging markets. These factors, it said, place the company at the forefront of delivering high-value pharma solutions.

Looking ahead, the brokerage expects Blue Jet's revenue growth to be fueled by its pipeline of new products in iodinated and gadolinium contrast media, novel chemical entity (NCE) intermediates, and i...